BACKGROUND: Elevated plasma N-terminal (NT)-proBNP levels and coronary calcium score (CCS) not only predicts myocardial ischaemia and coronary artery stenosis but also adverse cardiovascular events and mortality in type 2 diabetic patients with an increased urinary albumin excretion rate (UAER), whereas low levels are associated with low frequency of coronary artery disease (CAD) and good prognosis. The underlying causes of poor prognosis in patients with elevated NT-proBNP are not known; thus, we investigated the role of putative asymptomatic CAD in type 2 diabetic patients with UAER >30 mg/24 h and elevated P-NT-proBNP and/or CCS. METHODS: We identified 200 type 2 diabetic patients without known CAD and with normal creatinine levels. Patients with P-NT-proBNP >45.2 ng/L (the median P-NT-proBNP value in this cohort and in accordance with our previous findings) and/or CCS ≥ 400 were stratified as high-risk patients for CAD (n = 133) and all other patients as low-risk patients (n = 67). High-risk patients were examined by myocardial perfusion imaging (MPI; n = 109) and/or computer tomography angiography (n = 20) and/or coronary angiography (CAG; n = 86). RESULTS: All patients received intensive mulitifactorial intervention. In 70 of 133 (53%) high-risk patients, significant CAD was demonstrated by MPI and/or CAG, corresponding to 35% (70/200) of the total cohort. Among high-risk patients, CCS but not P-NT-proBNP was paralleled by increased prevalence of significant CAD and in the 86 patients where CAG was performed, a CCS <100 had a negative predictive value for coronary artery stenosis of 94% (P = 0.04). CONCLUSIONS: Our study revealed that >50% of asymptomatic type 2 diabetic patients with UAER >30 mg/24 h had significant CAD based on risk stratification with P-NT-proBNP and CCS. This provides some explanation to the previously reported poor prognosis in these asymptomatic patients. Optimized cardio protective treatment in these patients is warranted.
BACKGROUND: Elevated plasma N-terminal (NT)-proBNP levels and coronary calcium score (CCS) not only predicts myocardial ischaemia and coronary artery stenosis but also adverse cardiovascular events and mortality in type 2 diabeticpatients with an increased urinary albumin excretion rate (UAER), whereas low levels are associated with low frequency of coronary artery disease (CAD) and good prognosis. The underlying causes of poor prognosis in patients with elevated NT-proBNP are not known; thus, we investigated the role of putative asymptomatic CAD in type 2 diabeticpatients with UAER >30 mg/24 h and elevated P-NT-proBNP and/or CCS. METHODS: We identified 200 type 2 diabeticpatients without known CAD and with normal creatinine levels. Patients with P-NT-proBNP >45.2 ng/L (the median P-NT-proBNP value in this cohort and in accordance with our previous findings) and/or CCS ≥ 400 were stratified as high-risk patients for CAD (n = 133) and all other patients as low-risk patients (n = 67). High-risk patients were examined by myocardial perfusion imaging (MPI; n = 109) and/or computer tomography angiography (n = 20) and/or coronary angiography (CAG; n = 86). RESULTS: All patients received intensive mulitifactorial intervention. In 70 of 133 (53%) high-risk patients, significant CAD was demonstrated by MPI and/or CAG, corresponding to 35% (70/200) of the total cohort. Among high-risk patients, CCS but not P-NT-proBNP was paralleled by increased prevalence of significant CAD and in the 86 patients where CAG was performed, a CCS <100 had a negative predictive value for coronary artery stenosis of 94% (P = 0.04). CONCLUSIONS: Our study revealed that >50% of asymptomatic type 2 diabeticpatients with UAER >30 mg/24 h had significant CAD based on risk stratification with P-NT-proBNP and CCS. This provides some explanation to the previously reported poor prognosis in these asymptomatic patients. Optimized cardio protective treatment in these patients is warranted.
Authors: Emilie H Zobel; Bernt Johan von Scholten; Henrik Reinhard; Frederik Persson; Tine W Hansen; Hans-Henrik Parving; Peter K Jacobsen; Peter Rossing Journal: Diabetologia Date: 2017-07-05 Impact factor: 10.122
Authors: Bernt Johan von Scholten; Henrik Reinhard; Tine W Hansen; Jens Oellgaard; Hans-Henrik Parving; Peter K Jacobsen; Peter Rossing Journal: Diabetologia Date: 2016-03-31 Impact factor: 10.122
Authors: S S Roscioni; D de Zeeuw; M E Hellemons; H Mischak; P Zürbig; S J L Bakker; R T Gansevoort; H Reinhard; F Persson; M Lajer; P Rossing; H J Lambers Heerspink Journal: Diabetologia Date: 2012-10-20 Impact factor: 10.122
Authors: Henrik Reinhard; Mads Nybo; Peter R Hansen; Niels Wiinberg; Andreas Kjær; Claus L Petersen; Kaj Winther; Hans-Henrik Parving; Lars M Rasmussen; Peter Rossing; Peter K Jacobsen Journal: Cardiovasc Diabetol Date: 2011-07-29 Impact factor: 9.951
Authors: Henrik Reinhard; Niels Wiinberg; Peter R Hansen; Andreas Kjær; Claus L Petersen; Kaj Winther; Hans-Henrik Parving; Peter Rossing; Peter K Jacobsen Journal: Cardiovasc Diabetol Date: 2011-08-03 Impact factor: 9.951
Authors: Christel Joergensen; Henrik Reinhard; Anne Schmedes; Peter R Hansen; Niels Wiinberg; Claus L Petersen; Kaj Winther; Hans-Henrik Parving; Peter K Jacobsen; Peter Rossing Journal: Diabetes Care Date: 2011-10-31 Impact factor: 19.112
Authors: Henrik Reinhard; Peter R Hansen; Niels Wiinberg; Andreas Kjær; Claus L Petersen; Kaj Winther; Hans-Henrik Parving; Peter Rossing; Peter K Jacobsen Journal: Cardiovasc Diabetol Date: 2012-03-05 Impact factor: 9.951
Authors: Bernt Johan von Scholten; Henrik Reinhard; Tine Willum Hansen; Morten Lindhardt; Claus Leth Petersen; Niels Wiinberg; Peter Riis Hansen; Hans-Henrik Parving; Peter Karl Jacobsen; Peter Rossing Journal: Cardiovasc Diabetol Date: 2015-05-21 Impact factor: 9.951
Authors: Emilie H Zobel; Bernt Johan von Scholten; Henrik Reinhard; Frederik Persson; Tom Teerlink; Tine W Hansen; Hans-Henrik Parving; Peter K Jacobsen; Peter Rossing Journal: Cardiovasc Diabetol Date: 2017-07-11 Impact factor: 9.951
Authors: Henrik Reinhard; Ellen Garde; Arnold Skimminge; Per Åkeson; Thomas Zoëga Ramsøy; Kaj Winther; Hans-Henrik Parving; Peter Rossing; Peter K Jacobsen Journal: Cardiovasc Diabetol Date: 2012-10-03 Impact factor: 9.951